The prevalence of obesity is increasing which becomes worrisome due to its association with several diseases and certain types of cancers. While weight control through dietary caloric restriction and/or physical activity protects against cancer in animal models, the underlying mechanisms are not fully defined. Weight loss due to negative energy balance is associated with alterations of multiple growth factors and endocrine hormones. The altered hormones and hormone-related functions appear to be responsible for anti-cancer mechanisms. In this review, we summarize the recent studies related to weight loss and the altered endocrine hormones, focusing on the reduced levels of the mitogenic insulin-like growth factor 1 (IGF-1) and adipokine leptin as well as the raised levels of adiponectin and glucocorticoids. The potential molecular targets of these hormone-dependent signalling pathways are also discussed. Considering the increasing trends of obesity throughout the world, a better understanding of the underlying mechanisms between body weight, endocrine hormones and cancer risk may lead to novel approaches to cancer prevention and treatment.
GrabnerM. BMI trends, socioeconomic status, and the choice of dataset. Obes Facts2012; 5: 112–26.
2.
WangW. Editorial: weight control, endocrine hormones, and cancer prevention. J Nutr Food Sci2012; 2: e107–e107.
3.
CalleEERoriguezCWalker-ThurmondKThunMJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of US adults. N Engl J Med2003; 348: 1625–38.
4.
HallKDHeymsfieldSBKemnitzJWKleinSSchoellerDASpeakmanJR. Energy balance and its components: implications for body weight regulation. Am J Clin Nutr2012; 95: 989–94.
5.
Moreschi CZ. Beziehungen zwischen ernahrung und tumorwachstum. Immunitatsforsch 1909;2:651–75.
6.
KritchevskyD. Caloric restriction and experimental carcinogenesis. Adv Exp Med Biol1992; 322: 131–41.
7.
VainioHKaaksRBianchiniF. Weight control and physical activity in cancer prevention: international evaluation of the evidence. Eur J Cancer Prev2002; 2: S94–100.
8.
PatelAVFeigelsonHSTalbotJTMcCulloughMLRodriguezCPatelRCThunMJCalleEE. The role of body weight in the relationship between physical activity and endometrial cancer: results from a large cohort of US women. Int J Cancer2008; 123: 1877–82.
9.
InoueMYamamotoSKurahashiNIwasakiMSasazukiSTsuganeS. Japan public health center-based prospective study group. Daily total physical activity level and total cancer risk in men and women: results from a large-scale population-based cohort study in Japan. Am J Epidemiol2008; 168: 391–403.
10.
FriedenreichCMOrensteinMR. Physical activity and cancer prevention: etiologic evidence and biological mechanisms. J Nutr2002; 132: 3456S–64S.
11.
Hoffman-GoetzL. Physical activity and cancer prevention: animal-tumor models. Med Sci Sports Exerc2003; 35: 1828–33.
12.
DavisJMKohutMLJacksonDAColbertLHMayerEPGhaffarA. Exercise effects on lung tumor metastases and in vitro alveolar macrophage antitumor cytotoxicity. Am J Physiol1998; 274: R1454–9.
13.
Hoffman-GoetzLMayKMArumugamY. Exercise training and mouse mammary tumour metastasis. Anticancer Res1994; 14: 2627–31.
14.
RadakZGaalDTaylorAWKanekoTTaharaSNakamotoH GotoS. Attenuation of the development of murine solid leukemia tumor by physical exercise. Antioxid Redox Signal2002; 4: 213–19.
15.
XieLJiangYOuyangPChenJDoanHHerndonBSylvesterJEZhangKMolteniAReichleMZhangRHaubMDBaybuttRCWangW. Effects of dietary calorie restriction or exercise on the PI3K and Ras signaling pathways in the skin of mice. J Biol Chem2007; 282: 28025–35.
16.
MooreTCarbajalSBeltranLPerkinsSNYakarSLeroithDHurstingSDDigiovanniJ. Reduced susceptibility to two-stage skin carcinogenesis in mice with low circulating insulin-like growth factor I levels. Cancer Res2008; 68: 3680–8.
17.
KoernerAKratzschJKiessW. Adipocytokines: leptin – the classical, resistin – the controversical, adiponectin – the promising, and more to come. Best Pract Res Clin Endocrinol Metab2005; 19: 525–46.
18.
StewartJWKoehlerKJacksonWHawleyJWangWAuAMyersRBirtDF. Prevention of mouse skin tumor promotion by dietary energy restriction requires an intact adrenal gland and glucocorticoid supplementation restores inhibition. Carcinogenesis2005; 26: 1077–84.
19.
JiangYWangW. Potential mechanisms of cancer prevention by weight control. Biophys Rev Lett2008; 3: 421–37.
20.
KaaksR. Nutrition, insulin, IGF-1 metabolism and cancer risk: a summary of epidemiological evidence. Novartis Found Symp2004; 262: 247–60.
21.
WerohaSJHaluskaP. The insulin-like growth factor system in cancer. Endocrinol Metab Clin North Am2012; 41: 335–50.
22.
SureshbabuATonnerEFlintDJ. Insulin-like growth factor binding proteins and mammary gland development. Int J Dev Biol2011; 55: 781–9.
23.
KurmashevaRTHoughtonPJ. IGF-I mediated survival pathways in normal and malignant cells. Biochim Biophys Acta2006; 1766: 1–22.
24.
DeLellisKRinaldiSKaaksRJKolonelLNHendersonBLe MarchandL. Dietary and lifestyle correlates of plasma insulin-like growth factor-I (IGF-I) and IGF binding protein-3 (IGFBP-3): the multiethnic cohort. Cancer Epidemiol Biomarkers Prev2004; 13: 1444–51.
25.
ZhaoHGrossmanHBSpitzMRLernerSPZhangKWuX. Plasma levels of insulin-like growth factor-1 and binding protein-3, and their association with bladder cancer risk. J Urol2003; 169: 714–17.
26.
ChenCLewisSKVoigtLFitzpatrickAPlymateSRWeissNS. Prostate carcinoma incidence in relation to prediagnostic circulating levels of insulin-like growth factor I, insulin-like growth factor binding protein 3, and insulin. Cancer2005; 103: 76–84.
27.
PollakM. Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer2008; 8: 915–28.
28.
EcksteinNServanKHildebrandtBPolitzAvon JonquieresGWolf-KummethSNapierskiIHamacherAKassackMUBudcziesJBeierMDietelMRoyer-PokoraBDenkertCRoyerHD. Hyperactivation of the insulin-like growth factor receptor I signaling pathway is an essential event for cisplatin resistance of ovarian cancer cells. Cancer Res2009; 69: 2996–3003.
29.
CaoHWangGMengLShenHFengZLiuQDuJ. Association between Circulating Levels of IGF-1 and IGFBP-3 and lung cancer risk: a meta-analysis. PLoS One2012; 7: e49884–e49884.
30.
GiovannucciE. Insulin, insulin-like growth factors and colon cancer: a review of the evidence. J Nutr2001; 131: 3109S–20S.
31.
BolDKKiguchiKGimenez-ContiIRuppTDiGiovanniJ. Overexpression of insulin-like growth factor-1 induces hyperplasia, dermal abnormalities, and spontaneous tumor formation in transgenic mice. Oncogene1997; 14: 1725–34.
32.
DiGiovanniJBolDKWilkerEBeltranLCarbajalSMoatsSRamirezAJorcanoJKiguchiK. Constitutive expression of insulin-like growth factor-1 in epidermal basal cells of transgenic mice leads to spontaneous tumor promotion. Cancer Res2000; 60: 1561–70.
33.
WilkerELuJRhoOCarbajalSBeltranLDiGiovanniJ. Role of PI3K/Akt signaling in insulin-like growth factor-1 (IGF-1) skin tumor promotion. Mol Carcinog2005; 44: 137–45.
34.
JiangYMaHSuXChenJXuJStandardJLinDWangW. IGF-1 mediates exercise-induced phospholipid alteration in the murine skin tissues. J Nutr Food Sci2012, pp. S2–003.
35.
RuggeriBAKlurfeldDMKritchevskyDFurlanettoRW. Caloric restriction and 7,12-dimethylbenz(a)anthracene-induced mammary tumor growth in rats: alterations in circulating insulin, insulin-like growth factors I and II, and epidermal growth factor. Cancer Res1989; 49: 4130–4.
36.
OuyangPJiangYDoanHMXieLVasquezDWeltiRSuXLuNHerndonBYangSSJeannotteRWangW. Weight Loss via exercise with controlled dietary intake may affect phospholipid profile for cancer prevention in murine skin tissues. Cancer Prev Res (Phila)2010; 3: 466–77.
37.
XieLWangW. Weight control and cancer Prevention: role of IGF-1-mediated signaling pathways. Exp Biol Med2013; 238: 127–32.
38.
FontanaLKleinSHolloszyJO. Long-term low-protein, low-calorie diet and endurance exercise modulate metabolic factors associated with cancer risk. Am J Clin Nutr2006; 84: 1456–62.
39.
HurstingSDDigiovanniJDannenbergAJAzradMLeroithDDemark-WahnefriedWKakaralaMBrodieABergerNA. Obesity, energy balance, and cancer: new opportunities for prevention. Cancer Prev Res (Phila)2012; 5: 1260–72.
40.
FruhbeckGJebbSAPrenticeAM. Leptin: physiology and pathophysiology. Clin Physiol1998; 18: 399–419.
41.
FruhbeckG. A heliocentric view of leptin. Proc Nutr Soc2001; 60: 301–18.
42.
UngerRH. The hyperleptinemia of obesity-regulator of caloric surpluses. Cell2004; 117: 145–6.
43.
AhimaRSFlierJS. Leptin. Annu Rev Physiol2000; 62: 413–37.
44.
FruhbeckG. Peripheral actions of leptin and its involvement in disease. Nutr Rev2002; 60: S47–55; discussion S68-84.
45.
BjorbaekCKahnBB. Leptin signaling in the central nervous system and the periphery. Recent Prog Horm Res2004; 59: 305–31.
46.
GarofaloCSurmaczE. Leptin and cancer. J Cell Physiol2006; 207: 12–22.
FrankenberryKASkinnerHSomasundarPMcFaddenDWVona-DavisLC. Leptin receptor expression and cell signaling in breast cancer. Int J Oncol2006; 28: 985–93.
49.
SulkowskaMGolaszewskaJWincewiczAKodaMBaltaziakMSulkowskiS. Leptin – from regulation of fat metabolism to stimulation of breast cancer growth. Pathol Oncol Res2006; 12: 69–72.
50.
HardwickJCVan Den BrinkGROfferhausGJVan DeventerSJPeppelenboschMP. Leptin is a growth factor for colonic epithelial cells. Gastroenterology2001; 121: 79–90.
51.
LiuZUesakaTWatanabeHKatoN. High fat diet enhances colonic cell proliferation and carcinogenesis in rats by elevating serum leptin. Int J Oncol2001; 19: 1009–14.
52.
HousaDHousovaJVernerovaZHaluzikM. Adipocytokines and cancer. Physiol Res2006; 55: 233–44.
53.
IshigakiTKoyamaKTsujitaJTanakaNHoriSOkuY. Plasma leptin levels of elite endurance runners after heavy endurance training. J Physiol Anthropol Appl Human Sci2005; 24: 573–8.
54.
FinlaysonCAChappellJLeitnerJWGoalstoneMLGarrityMNawazSCiaraldiTPDrazninB. Enhanced insulin signaling via Shc in human breast cancer. Metabolism2003; 52: 1606–11.
55.
PowellDRSuwanichkulACubbageMLDePaolisLASnuggsMBLeePD. Insulin inhibits transcription of the human gene for insulin-like growth factor-binding protein-1. J Biol Chem1991; 266: 18868–76.
56.
UnderwoodLEThissenJPLemozySKetelslegersJMClemmonsDR. Hormonal and nutritional regulation of IGF-I and its binding proteins. Horm Res1994; 42: 145–51.
57.
BjorkJNilssonJHultcrantzRJohanssonC. Growth-regulatory effects of sensory neuropeptides, epidermal growth factor, insulin, and somatostatin on the non-transformed intestinal epithelial cell line IEC-6 and the colon cancer cell line HT 29. Scand J Gastroenterol1993; 28: 879–84.
58.
PandiniGVigneriRCostantinoAFrascaFIppolitoAFujita-YamaguchiYSiddleKGoldfineIDBelfioreA. Insulin and insulin-like growth factor-I (IGF-I) receptor overexpression in breast cancers leads to insulin/IGF-I hybrid receptor overexpression: evidence for a second mechanism of IGF-I signaling. Clin Cancer Res1999; 5: 1935–44.
59.
ArcidiaconoBIiritanoSNoceraAPossidenteKNevoloMTVenturaVFotiDChiefariEBrunettiA. Insulin resistance and cancer risk: an overview of the pathogenetic mechanisms. Exp Diabetes Res2012; 2012: 789174–789174.
60.
ZhuZJiangWMcGinleyJWolfePThompsonHJ. Effects of dietary energy repletion and IGF-1 infusion on the inhibition of mammary carcinogenesis by dietary energy restriction. Mol Carcinog2005; 42: 170–6.
61.
Paz-FilhoGLimELWongMLLicinioJ. Associations between adipokines and obesity-related cancer. Front Biosci2011; 16: 1634–50.
62.
ShehzadAIqbalWShehzadOLeeY. Adiponectin: regulation of its production and its role in human diseases. Hormones2012; 11: 8–20.
63.
ChenDCChungYFYehYTChaungHCKuoFCFuOYChenHYHouMFYuanSS. Serum adiponectin and leptin levels in Taiwanese breast cancer patients. Cancer Lett2006; 237: 109–14.
64.
KangJHLeeYYYuBYYangBSChoKHYoonDKRohYK. Adiponectin induces growth arrest and apoptosis of MDA-MB-231 breast cancer cell. Arch Pharm Res2005; 28: 1263–9.
65.
GoktasSYilmazMICaglarKSonmezAKilicSBedirS. Prostate cancer and adiponectin. Urology2005; 65: 1168–72.
66.
IshikawaMKitayamaJKazamaSHiramatsuTHatanoKNagawaH. Plasma adiponectin and gastric cancer. Clin Cancer Res2005; 11: 466–72.
67.
WeiEKGiovannucciEFuchsCSWillettWCMantzorosCS. Low plasma adiponectin levels and risk of colorectal cancer in men: a prospective study. J Natl Cancer Inst2005; 97: 1688–94.
68.
ZhuMMiuraJLuLXBernierMDeCaboRLaneMARothGSIngramDK. Circulating adiponectin levels increase in rats on caloric restriction: the potential for insulin sensitization. Exp Gerontol2004; 39: 1049–59.
69.
BarnholtKEHoffmanARRockPBMuzaSRFulcoCSBraunBHollowayLMazzeoRSCymermanAFriedlanderAL. Endocrine responses to acute and chronic high-altitude exposure (4,300 meters): modulating effects of caloric restriction. Am J Physiol Endocrinol Metab2006; 290: E1078–88.
70.
JamurtasAZTheocharisVKoukoulisGStakiasNFatourosIGKouretasDKoutedakisY. The effects of acute exercise on serum adiponectin and resistin levels and their relation to insulin sensitivity in overweight males. Eur J Appl Physiol2006; 97: 122–6.
71.
OberbachATonjesAKlotingNFasshauerMKratzschJBusseMWPaschkeRStumvollMBluherM. Effect of a 4 week physical training program on plasma concentrations of inflammatory markers in patients with abnormal glucose tolerance. Eur J Endocrinol2006; 154: 577–85.
72.
YokotaTOritaniKTakahashiIIshikawaJMatsuyamaAOuchiNKiharaSFunahashiTTennerAJTomiyamaYMatsuzawaY. Adiponectin, a new member of the family of soluble defense collagens, negatively regulates the growth of myelomonocytic progenitors and the functions of macrophages. Blood2000; 96: 1723–32.
73.
DieudonneMNBussiereMDos SantosELeneveuMCGiudicelliYPecqueryR. Adiponectin mediates antiproliferative and apoptotic responses in human MCF7 breast cancer cells. Biochem Biophys Res Commun2006; 345: 271–9.
74.
ZhuZJiangWZacherJHNeilESMcGinleyJNThompsonHJ. Effects of energy restriction and wheel running on mammary carcinogenesis and host systemic factors in a rat model. Cancer Prev Res (Phila)2012; 5: 414–22.
75.
SoAYChaivorapolCBoltonECLiHYamamotoKR. Determinants of cell- and gene-specific transcriptional regulation by the glucocorticoid receptor. PLoS Genet2007; 3: e94–e94.
76.
JohnSJohnsonTASungMHBiddieSCTrumpSKoch-PaizCADavisSRWalkerRMeltzerPSHagerGL. Kinetic complexity of the global response to glucocorticoid receptor action. Endocrinology2009; 150: 1766–74.
77.
DiamondMIMinerJNYoshinagaSKYamamotoKR. Transcription factor interactions: selectors of positive or negative regulation from a single DNA element. Science1990; 249: 1266–72.
78.
StocklinEWisslerMGouilleuxFGronerB. Functional interactions between Stat5 and the glucocorticoid receptor. Nature1996; 383: 726–8.
79.
SubramaniamNCampionJRafterIOkretS. Cross-talk between glucocorticoid and retinoic acid signals involving glucocorticoid receptor interaction with the homoeodomain protein Pbx1. Biochem J2003; 370: 1087–95.
80.
GursoyECardounelAHuYKalimiM. Biological effects of long-term caloric restriction: adaptation with simultaneous administration of caloric stress plus repeated immobilization stress in rats. Exp Biol Med2001; 226: 97–102.
81.
BirtDFYaktineADuysenE. Glucocorticoid mediation of dietary energy restriction inhibition of mouse skin. Carcinogenesis. J Nutr1999; 129: 571S–74S.
82.
ZhuZJiangWThompsonHJ. Effect of corticosterone administration on mammary gland development and p27 expression and their relationship to the effects of energy restriction on mammary carcinogenesis. Carcinogenesis1998; 19: 2101–6.
83.
ZhuZJiangWThompsonHJ. Mechanisms by which energy restriction inhibits rat mammary carcinogenesis: in vivo effects of corticosterone on cell cycle machinery in mammary carcinomas. Carcinogenesis2003; 24: 1225–31.
84.
PashkoLLSchwartzAG. Reversal of food restriction-induced inhibition of mouse skin tumor promotion by adrenalectomy. Carcinogenesis1992; 13: 1925–8.
85.
PashkoLLSchwartzAG. Inhibition of 7,12-dimethylbenz[a]anthracene-induced lung tumorigenesis in A/J mice by food restriction is reversed by adrenalectomy. Carcinogenesis1996; 17: 209–12.
86.
ZhuZJiangWThompsonHJ. An experimental paradigm for studying the cellular and molecular mechanisms of cancer inhibition by energy restriction. Mol Carcinogen2002; 35: 51–6.
